Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5015-5021

  Caughlan, Ruth E ^a   Sriram, Shubha ^a,b   Daigle, Denis M ^a,c   Woods, Angela L ^a   Buco, Jennifer ^a   Peterson, Ron L ^a   Dzink Fox, JoAnn ^a   Walker, Susan ^a   Dean, Charles R ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Protez Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; METHIONINE TRANSFER RNA; MEXXY PROTEIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; PEPTIDE DEFORMYLASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; CONTROL GROUP; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; UPREGULATION;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC COMPLEMENTATION TEST; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS; PEPTIDES; PSEUDOMONAS AERUGINOSA; TETRACYCLINE; TRIMETHOPRIM;

EID: 71249136374     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00253-09     Document Type: Article

References (47)

1. Apfel, C., D. W. Banner, D. Bur, M. Dietz, T. Hirata, C. Hubschwerlen, H. Locher, M. G. Page, W. Pirson, G. Rosse, and J. L. Specklin. 2000. Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J. Med. Chem. 43:2324-2331.
2. Apfel, C. M., H. Locher, S. Evers, B. Takacs, C. Hubschwerlen, W. Pirson, M. G. Page, and W. Keck. 2001. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. 45:1058-1064.
3. Balakrishnan, A., B. Patel, S. A. Sieber, D. Chen, N. Pachikara, G. Zhong, B. F. Cravatt, and H. Fan. 2006. Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J. Biol. Chem. 281:16691-16699.
4. Becher, A., and H. P. Schweizer. 2000. Integration-proficient Pseudomonas aeruginosa vectors for isolation of single-copy chromosomal lacZ and lux gene fusions. BioTechniques 29:948-950, 952. (Pubitemid 30845826)
5. Bell, J. M., J. D. Turnidge, M. Inoue, S. Kohno, Y. Hirakata, Y. Ono, and R. N. Jones. 2005. Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. J. Antimicrob. Chemother. 55:276-278.
6. Bingel-Erlenmeyer, R., R. Kohler, G. Kramer, A. Sandikci, S. Antolic, T. Maier, C. Schaffitzel, B. Wiedmann, B. Bukau, and N. Ban. 2008. A peptide deformylase-ribosome complex reveals mechanism of nascent chain processing. Nature 452:108-111. (Pubitemid 351355096)
7. Cao, L., R. Srikumar, and K. Poole. 2004. MexAB-OprM hyperexpression in NalC-type multidrug-resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719. Mol. Microbiol. 53:1423-1436.
8. Chen, D., C. Hackbarth, Z. J. Ni, C. Wu, W. Wang, R. Jain, Y. He, K. Bracken, B. Weidmann, D. V. Patel, J. Trias, R. J. White, and Z. Yuan. 2004. Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob. Agents Chemother. 48:250-261.
9. Chen, D. Z., D. V. Patel, C. J. Hackbarth, W. Wang, G. Dreyer, D. C. Young, P. S. Margolis, C. Wu, Z. J. Ni, J. Trias, R. J. White, and Z. Yuan. 2000. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39:1256-1262.
10. CLSI. 2006. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically (M7-A7). CLSI, Wayne, PA.
11. Credito, K., G. Lin, L. M. Ednie, and P. C. Appelbaum. 2004. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. 48:4033-4036.
12. Dean, C. R., C. V. Franklund, J. D. Retief, M. J. Coyne, Jr., K. Hatano, D. J. Evans, G. B. Pier, and J. B. Goldberg. 1999. Characterization of the serogroup O11 O-antigen locus of Pseudomonas aeruginosa PA103. J. Bacteriol. 181:4275-4284.
13. Dean, C. R., S. Narayan, D. M. Daigle, J. L. Dzink-Fox, X. Puyang, K. R. Bracken, K. E. Dean, B. Weidmann, Z. Yuan, R. Jain, and N. S. Ryder. 2005. Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415. Antimicrob. Agents Chemother. 49:3129-3135.
14. Dean, C. R., M. A. Visalli, S. J. Projan, P. E. Sum, and P. A. Bradford. 2003. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 47:972-978.
15. Ednie, L. M., G. Pankuch, and P. C. Appelbaum. 2004. Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. 48:4027-4032.
16. El'Garch, F., K. Jeannot, D. Hocquet, C. Llanes-Barakat, and P. Plesiat. 2007. Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 51:1016-1021.
17. Fritsche, T. R., H. S. Sader, R. Cleeland, and R. N. Jones. 2005. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob. Agents Chemother. 49:1468-1476.
18. Hackbarth, C. J., D. Z. Chen, J. G. Lewis, K. Clark, J. B. Mangold, J. A. Cramer, P. S. Margolis, W. Wang, J. Koehn, C. Wu, S. Lopez, G. Withers III, H. Gu, E. Dunn, R. Kulathila, S. H. Pan, W. L. Porter, J. Jacobs, J. Trias, D. V. Patel, B. Weidmann, R. J. White, and Z. Yuan. 2002. N-Alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. 46:2752-2764.
19. Hirakata, Y., R. Srikumar, K. Poole, N. Gotoh, T. Suematsu, S. Kohno, S. Kamihira, R. E. Hancock, and D. P. Speert. 2002. Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J. Exp. Med. 196:109-118.
20. Hoang, T. T., R. R. Karkhoff-Schweizer, A. J. Kutchma, and H. P. Schweizer. 1998. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 212:77-86.
21. Jeannot, K., M. L. Sobel, F. El Garch, K. Poole, and P. Plesiat. 2005. Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction. J. Bacteriol. 187:5341-5346.
22. Jones, R. N., T. R. Fritsche, and H. S. Sader. 2004. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. Diagn. Microbiol. Infect. Dis. 49:63-65.
23. Jones, R. N., G. J. Moet, H. S. Sader, and T. R. Fritsche. 2004. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. J. Antimicrob. Chemother. 53:804-807.
24. Jones, R. N., H. S. Sader, and T. R. Fritsche. 2005. Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis). Diagn. Microbiol. Infect. Dis. 51:139-141. (Pubitemid 40215425)
25. Kumar, A., and H. P. Schweizer. 2005. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv. Drug Deliv. Rev. 57:1486-1513.
26. Leeds, J., C. Dean, B. Favre, J. Dzink-Fox, M. Sachdeva, S. Narayan, J. Medeiros, and N. Ryder. 2004. In vitro selection of decreased susceptibility to the novel peptide deformylase inhibitor LBM415 in three pathogens, abstr. C1-1880, p. 88. Abstr. 44th Annu. Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
27. Leeds, J. A., and C. R. Dean. 2006. Peptide deformylase as an antibacterial target: a critical assessment. Curr. Opin. Pharmacol. 6:445-452.
28. Linares, J. F., J. A. Lopez, E. Camafeita, J. P. Albar, F. Rojo, and J. L. Martinez. 2005. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa. J. Bacteriol. 187:1384-1391.
29. Margolis, P., C. Hackbarth, S. Lopez, M. Maniar, W. Wang, Z. Yuan, R. White, and J. Trias. 2001. Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob. Agents Chemother. 45:2432-2435. (Pubitemid 32801891)
30. Margolis, P. S., C. J. Hackbarth, D. C. Young, W. Wang, D. Chen, Z. Yuan, R. White, and J. Trias. 2000. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. 44:1825-1831.
31. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:2242-2246.
32. Morita, Y., C. Gilmour, D. Metcalf, and K. Poole. 2009. Translational control of the antibiotic inducibility of the PA5471 gene required for mexXY multidrug efflux gene expression in Pseudomonas aeruginosa. J. Bacteriol. 191:4966-4975.
33. Morita, Y., M. L. Sobel, and K. Poole. 2006. Antibiotic inducibility of the MexXY multidrug efflux system of Pseudomonas aeruginosa: involvement of the antibiotic-inducible PA5471 gene product. J. Bacteriol. 188:1847-1855.
34. Newton, D. T., C. Creuzenet, and D. Mangroo. 1999. Formylation is not essential for initiation of protein synthesis in all eubacteria. J. Biol. Chem. 274:22143-22146.
35. Nilsson, A. I., A. Zorzet, A. Kanth, S. Dahlstrom, O. G. Berg, and D. I. Andersson. 2006. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc. Natl. Acad. Sci. USA 103:6976-6981.
36. Poole, K. 2004. Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect. 10:12-26.
37. Poole, K. 2001. Multidrug resistance in Gram-negative bacteria. Curr. Opin. Microbiol. 4:500-508.
38. Poole, K. 2002. Outer membranes and efflux: the path to multidrug resistance in Gram-negative bacteria. Curr. Pharm. Biotechnol. 3:77-98.
39. Poole, K., and R. Srikumar. 2001. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr. Top. Med. Chem. 1:59-71.
40. Sánchez, L., W. Pan, M. Viñas, and H. Nikaido. 1997. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J. Bacteriol. 179:6855-6857.
41. Schweizer, H. D. 1993. Small broad-host-range gentamycin resistance gene cassettes for site-specific insertion and deletion mutagenesis. BioTechniques 15:831-834. (Pubitemid 2011273)
42. Simon, R., M. O'Connel, M. Iabes, and A. Puhler. 1986. Plasmid vectors for the genetic analysis and manipulation of Rhizobia and other gram negative bacteria. Methods. Enzymol. 111:640-649.
43. Sobel, M. L., D. Hocquet, L. Cao, P. Plesiat, and K. Poole. 2005. Mutations in PA3574 (nalD) lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:1782-1786.
44. Sobel, M. L., G. A. McKay, and K. Poole. 2003. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 47:3202-3207.
45. Srikumar, R., C. J. Paul, and K. Poole. 2000. Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-OprM multidrug efflux system of Pseudomonas aeruginosa. J. Bacteriol. 182:1410-1414. (Pubitemid 30104421)
46. Trepod, C. M., and J. E. Mott. 2004. Identification of the Haemophilus influenzae tolC gene by susceptibility profiles of insertionally inactivated efflux pump mutants. Antimicrob. Agents Chemother. 48:1416-1418.
47. Watters, A. A., R. N. Jones, J. A. Leeds, G. Denys, H. S. Sader, and T. R. Fritsche. 2006. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). J. Antimicrob. Chemother. 57:914-923.